Table 2.

MicroRNAs modulated by bioactive compounds; the effect on human normal or cancer cells.

Compound	miRNA	Reference	Cells/Cancer	Dose/Duration
EGCG	miR-18, miR-16, let-7a, miR-221, miR-34b, miR-193b, miR-222, miR-342	[29]	hepatic cancer	100 μM, 24 h
	miR-636, miR-3907	[30]	normal dermal fibroblasts	10 μM, 24 h
	miR-200c	[31]	colorectal cancer cells and colon cancer stem cells	100 μM, 24 h
	miR-210, miR-98-5p	[32,33]	lung cancer	40 μM, 9 h 10 μM, 24 h
	miR-1, miR-126	[34,35]	osteosarcoma	0.08 g/L, 48 h 0.2 g/L, 72 h
	miR-194	[36]	hepatocarcinoma	10 μg/mL, 48 h
	miR-7-1, miR-34a, miR-99a, miR-92, miR-93, miR-106b	[37,38]	neuroblastoma	50 μM, 24 h
	miR-25, miR-92, miR-141, miR-200a	[39]	Hela cells and lymphoblasts	1–5 μM, 24 h
	miR-33a, miR-122	[40]	hepatocarcinoma	50 μM, 1 h
EGCG	miR-92, miR-93, miR-106b, miR-7-1, miR-34a, miR-99a	[41]	neuroblastoma	50 μM, 24 h
	miR-467bn, miR-487b, miR-197, miR-805, miR-374n, let-7f, miR-350, miR-24-1n, miR-137, miR-335-3p, let-7a, miR-222, miR-26b, miR-30c-1n, let-7d, miR-98, miR-30c, miR-30bn, miR-32, miR-674n, miR-532-5p, let-7g, miR-18a, miR-192, miR-302d, miR-30b, miR-802, let-7e, miR-322, miR-720, miR-146b, miR-340-3p, miR-185, miR-425, miR-10a, miR-126-5p, miR-101a, miR-30en, let-7c, miR-141, miR-33, miR-29an, miR-199b, miR-450a-5p, miR-21, miR-23a, miR-101b, miR-148a, miR-193, miR-23b, miR-107, miR-140, miR-551b, miR-466c-5p, miR-106a, miR-590-3p, miR-875-3p, miR-224, miR-292-5p, miR-678, miR-469, let-7bn, miR-463n, miR-574-3p, miR-201, miR-290-3p, miR-181a, miR-302a, miR-429, miR-133a, miR-190b, miR-710, miR-135b, miR-296-5p, miR-191n, miR-188-5p, miR-298, miR-181a-1n, miR-466g, miR-26bn, miR-466f-3p, miR-29bn, miR-1224, miR-291b-5p, miR-324-5p, miR-486, miR-128, miR-450b-3p, miR-135an, miR-294, miR-671-5p, miR-878-3p, miR-801, miR-370, miR-1, miR-494, miR-133b	[41]	hepatocarcinoma	100 μM, 24 h
CRC	miR-192-5p/215	[42]	lung cancer	15 μM, 48 h
	miR-7	[43]	pancreatic cancer	3–6 μM, 72 h
	miR-22	[44,45]	retinoblastoma	20 μM, 48 h
	miR-27a	[46]	colon cancer	2.5–10 μg/mL, 24 h
	miR-21	[47]
	let-7a, miR-21, miR-34a	[48]	esophageal cancer	30 μM, 24 h
	miR-221	[44,49]	pancreatic cancer	500 nM of synthetic CRC analogue, 72 h
CRC	miR-27a, miR-20a, miR-17-5p, miR-21	[41]	colon carcinoma	30 μM, 24 h
	miR-203	[41]	bladder carcinoma	10 μM, 3 days
	miR-320, miR-26a, let-7i, miR-130a, miR-16, miR-125b, miR-23a, miR-27b, miR-155, miR-625, miR-576-3p, miR-186n, miR-9n, let-7i	[50]	lung adenocarcinoma	15 μM, 48 h
	miR-15a, miR-16-1	[41]	leukemic cells	5–20 μM, 24-72 h
	miR15a, miR-16	[51]	breast cancer	10–60 μM, 24 h
	miR-103, miR-140, miR-146b, miR-148a, miR-15b, miR-181a, miR-181b, miR-181d, miR-195, miR-196a, miR-199an, miR-19a, miR-204, miR-20a, miR-21, miR-22, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-27a, miR-34a, miR-374, miR-510, miR-7, miR-92, miR-93, miR-98	[41]	pancreatic cancer	10 μM, 72 h
RSV	miR-663, miR-744m	[44,52]	breast cancer	100 μM, 24 h
	miR-21	[44,53]	pancreatic cancer	50 μM, 24 h
	miR-520h	[54]	lung cancer	10–20 μM, 48 h
	miR-21, miR-181b, miR-663, miR-30c2	[55]	peripheral blood mononuclear cells from hypertensive patients	RSV (8 mg) grape extract, one year daily intake ( in vivo study)
	miR-150, miR-296-5p	[56]	lymph node cancer prostate	50 μM, 24 h
	miR-33a, miR-122	[40]	hepatocarcinoma	50 μM, 1 h
	miR-155 miR-663	[57]	monocytic cells	30–50 μM, 14 h
RSV	miR-155, miR-34a	[58]	EBV-immortalized B cells	25–50 μM, 24 h
	miR-7, miR-17, miR-18b, miR-20a, miR-20b, miR-92b, miR-106a, miR106b, miR-17-5p, miR-20a, miR-106b, miR-17-92 cluster, miR-106ab clusters	[59]	prostate cancer	50–100 μM, 24 h
	miR-622	[41]	bronchial epithelial cells	50 μM, 48 h
	miR-155, miR-633	[41]	monocytes	30 μM, 14 h
	let-7c, miR-106a, miR-106b, miR-1224-5p, miR-1228, miR-231, miR-1246, miR-1260, miR-1267, miR-1268, miR-129, miR-1290, miR-1308, miR-1469, miR-149, miR-150, miR-152, miR-15a, miR-17, miR-1825, miR-185, miR-18b, miR-1908, miR-1915, miR-197, miR-1972, miR-1973, miR-1974, miR-1975, miR-1977, miR-1979, miR-20a, miR-20b, miR-24, miR-296-5p, miR-483-5p, miR-513a-5p, miR-548q, miR-572, miR-575, miR-612, miR-638, miR-654-5p, miR-659, miR-671-5p, miR-7, miR-762, miR-764, miR-874, miR-92b, miR-939	[41]	lymph node cancer prostate	50 μM, 48 h
	miR-1, miR-100-1/2, miR-102, miR-103-1, miR-103-2, miR-146a, miR-146b-5p, miR-16-0, miR-17, miR-181a2, miR-194-2, miR-196a1, miR-205, miR-206, miR-21, miR-23a, miR-23b, miR-25, miR-26a, miR-29c, miR-30a-3p, miR-30c-1, miR-30d, miR-30e-5p, miR-323, miR-340, miR-363n-5p, miR-424, miR-494, miR-497, miR-560, miR-560, miR-565, miR-565, miR-572, miR-574, miR-594, miR-615, miR-622, miR-629, miR-631, miR-638, miR-639, miR-657, miR-659, miR-663, miR-801, miR-92a-2	[41]	colorectal carcinoma	50 μM, 14 h
n3-PUFA	miR-192, miR-30c, miR-141-3p, miR-221-3p, miR-1283, let-7f, miR-181a-5p, miR-1, miR-30a	[60]	Caco-2 cells	200 μM DHA in lipid micelles, 24 h
n3-PUFA	miR-26a, miR-26b	[61]	cholangiocarcinoma	50 μM DHA, 12 h
	miR-221	[62]	endothelial progenitor cells	25–125 μM EPA, 4 h
	miR-146, miR-181a	[63]	glioma	25–50 μM DHA, 48 h
	miR-21	[64]	breast cancer	152 nM DHA, 24 h
	miR-30c, miR-20b, miR-16, miR-22, miR-145, miR-34, miR-25, miR-17, miR-26a, miR-29c, miR-200a, miR-206, miR-323, miR-16, miR-22, miR-20b, miR-30c, miR-183, miR-224, miR-145, miR-181a, miR-208, miR-143, miR-20a, miR-149, miR-125b	[19,65]	glioma	50–100 μM DHA, 24 h